Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetadote in Newly Diagnosed Glioblastoma
NCT07387666Phase 1Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetylcysteine in glioblastoma (GBM), sponsored by UT Southwestern Medical Center. Primary endpoint: Effect of Acetadote on glioblastoma metabolism as measured by MRS at Day 21. Started Jun 2026; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07387666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387666.